<DOC>
	<DOCNO>NCT02044510</DOCNO>
	<brief_summary>The propose study randomize , double blind placebo control multicenter study determine effectiveness mirabegron treatment neurogenic bladder dysfunction . Patients randomize one two trial arm : mirabegron 25mg two week , escalation 50mg remain 8 week , match placebo capsule two week , placebo escalation remain 8 week . Each trial arm stratify base whether patient already take anticholinergic medication . The study treat total 144 patient ( 72 placebo , 72 mirabegron ) . The study hypothesis mirabegron result statistically superior ( increase ) urodynamic bladder capacity . The study duration 12 week , 1-4 week run period active placebo treatment administer . The primary outcome measure base increase urodynamic bladder capacity . Secondary outcome measure additional urodynamic parameter , urinary symptom scale , urinary quality life index , void diary result . Patients 18 year age diagnosis multiple sclerosis spinal cord injury eligible participate . All eligible patient urodynamic study perform within 4 week trial enrollment , end study ( week 9-10 ) . Adverse event study outcome assess predefined study time point .</brief_summary>
	<brief_title>Urodynamic Clinical Efficacy Mirabegron Neurogenic Bladder Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Inclusion criterion : Diagnosis traumatic nontraumatic suprasacral SCI multiple sclerosis ( base neurologist assessment and/or McDonald criterion ) ( 28 ) Age &gt; 18 year Stable method bladder management &gt; 3months ( either spontaneous provoke voiding , intermittent catheterization ) . Bothersome urinary symptom ( urinary frequency , urgency , urgency incontinence base standard ICS definition ( 29 ) ) complete 3 day void diary demonstrate least 1 episode nonstress base urinary incontinence 72hr period ( may urgency base incontinence unaware incontinence ) . Patient able read speak English Exclusion criterion : Based Screening visit history : Participation another drug device study 60 day prior screen visit . Previous urologic surgery : Transurethral prostatectomy , bladder augmentation , sphincterotomy , bladder neck sling , artificial urinary sphincter , catheterizable channel , implantable electrostimulator/neuromodulator Current use suprapubic catheter/foley catheter Unstable cardiac disease ( uncontrolled hypertension , myocardial infarction , unstable angina , severe congestive heart failure ( NYHA 3 4 ) , ventricular arrhythmia ( torsades de pointes ) , stroke within last 6 month ) Clinically significant abnormal ECG The investigator believe patient increase risk QT prolongation ( base review screen ECG patient concurrent medication ) History significant renal dysfunction within 1 year , serum creatinine &gt; 150umol/L screen visit ( visit 1 ) . History significant liver disease within 1 year , serum AST/ALT &gt; 2 time upper limit normal , GGT &gt; 3 time upper limit normal , total bilirubin &gt; 2 time upper limit normal screen visit ( visit 1 ) . History pelvic radiation History bladder cancer History concurrent malignancy cancer ( except noninvasive skin cancer ) within last 5 year . Subjects history cancer consider eligible subject undergone potentially curative therapy subject consider disease free least 5 year ( exception basal cell squamous cell carcinoma skin ) . Patient history interstitial cystitis/pelvic pain syndrome Patient history acute chronic urinary retention within last 3 month , currently use intermittent catheter Patient history tachyarrhythmia Patient history glaucoma Patient medical condition may cause noncompliance study protocol In opinion Investigator patient history significant stress urinary incontinence Patient sign symptom active urinary tract infection ( symptoms dysuria , foul smell urine , cloudy urine , increased spasticity , increase autonomic dysreflexia , self report fever , increase incontinence , back/suprapubic pain ) . Patient submit urine culture sensitivity , undergo treatment , eligible rescreening treatment . Female patient pregnant breastfeeding , plan become pregnant . Male patient plan father child study 28 day last dose study drug , plan donate sperm Patient refuse provide write consent Patient unable unwilling complete questionnaire study visit In opinion study investigator , patient 's best interest enrol study . Based medication allergy review The new addition anticholinergic medication , change anticholinergic dose , within last 30 day , ( bladder specific anticholinergic include oxybutynin , tolterodine , fesoterodine , solifenacin , darifenacin , trospium , hyoscine , oxybutynin gel patch , atropine , benzatropine ) . If previously use discontinue , medication must stop &gt; 2 week Newly add bladder active medication ( dose change ) within last 2 month ( Tamsulosin , Silodosin , Terazosin , Baclofen , Diazepam , amitriptyline , Finasteride , Dutasteride , DDAVP/desmopressin ) Use flecainide , propafenone , donepezil , thioridazine , tramadol , aripiprazole , desipramine , imipramine , venlafaxine digoxin Intravesical onabotulinum toxin use within last 1 year Intravesical oxybutynin within last 3 month Patient previous history treatment mirabegron Patient know allergy mirabegron previous adverse reaction beta 3 agonist . Based physical exam Patient postvoid residual &gt; 250mL study enrollment repeat test ( 1 attempt revoid ensure complete empty bladder ) use intermittent catheter Patient rest BP &gt; 180 mmHg systolic and/or &gt; 110 mmHg diastolic 2 minute sit quietly Patient rest heart rate &gt; 100bpm 2 minute sit quietly In opinion study investigator , patient 's best interest enrol study base clinically significant abnormality physical exam .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Spinal Cord Injuries</keyword>
	<keyword>mirabegron</keyword>
	<keyword>Urodynamics</keyword>
</DOC>